Chardan Capital Reiterates Hold Rating for Vistagen Therapeutics (NASDAQ:VTGN)
Vistagen Therapeutics (NASDAQ:VTGN)‘s stock had its “hold” rating reaffirmed by analysts at Chardan Capital in a report issued on Sunday, November 3rd, AnalystRatings.com reports. They presently have a $0.70 price objective on the stock. Chardan Capital’s price target points to a potential downside of 35.19% from the stock’s current price.
Several other brokerages also recently commented on VTGN. ValuEngine upgraded shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. William Blair reiterated a “buy” rating on shares of Vistagen Therapeutics in a research note on Wednesday, October 9th. Finally, Maxim Group set a $4.00 price objective on shares of Vistagen Therapeutics and gave the company a “buy” rating in a research note ...